Table 1.
Baseline Characteristics and Clinicopathologic Variables by Obesity
| Variable | None (BMI <30) | Obese (BMI ≥30) | p-value |
|---|---|---|---|
| N=171 | N=102 | ||
| Age (n=273) | |||
| <50 | 75 (44%) | 44 (43%) | 0.91 |
| 50+ | 96 (56%) | 58 (57%) | |
| Race/Ethnicity (n=268) | |||
| Non-Hispanic White | 65 (39%) | 26 (26%) | <0.01 |
| Non-Hispanic Black | 35 (21%) | 31 (31%) | |
| Hispanic | 53 (32%) | 42 (41%) | |
| Asian/Other | 14 (8%) | 2 (2%) | |
| Clinical Stage (n=270) | |||
| I/II | 111 (66%) | 60 (59%) | 0.30 |
| III | 58 (34%) | 41 (41%) | |
| Clinical Size (n=273) | |||
| 0–2cm | 29 (17%) | 10 (10%) | 0.16 |
| >2–5cm | 107 (63%) | 64 (63%) | |
| >5cm | 35 (20%) | 28 (27%) | |
| Grade(n=270) | |||
| Low (I or II) | 60 (36%) | 32 (31%) | 0.47 |
| High (III) | 108 (64%) | 70 (69%) | |
| Subtype (n=273) | |||
| Hormone Receptor +/HER2− | 86 (50%) | 49 (48%) | 0.89 |
| HER2+ | 57 (33%) | 37 (36%) | |
| Triple Negative Breast Cancer | 28 (17%) | 16 (16%) | |
| Surgery Type (n=272) | |||
| Lumpectomy | 56 (33%) | 35 (35%) | 0.75 |
| Mastectomy | 115 (67%) | 66 (65%) | |
| RT (n=267) | |||
| Yes | 136 (82%) | 86 (85%) | 0.50 |
| No | 30 (18%) | 15 (15%) | |
| Hormonal Therapy (n=258) | |||
| Yes | 116 (72%) | 77 (79%) | 0.19 |
| No | 45 (28%) | 20 (21%) | |
| Trastuzumab (n=258) | |||
| Yes | 55 (34%) | 37 (39%) | 0.46 |
| No | 107 (66%) | 59 (61%) | |
| Diabetes (n=272) | |||
| Yes | 22 (13%) | 30 (30%) | <0.01 |
| No | 149 (87%) | 71 (70%) |
RT – Radiation Therapy